You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/70452
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOrtolan, Érika Veruska Paiva-
dc.contributor.authorBustamante, Thais França-
dc.contributor.authorTakegawa, Bonifácio Katsunori-
dc.contributor.authorMendonça, Fernanda Alves-
dc.contributor.authorRodrigues, Antonio Marcos-
dc.contributor.authorMendes, Élson Felix-
dc.date.accessioned2014-05-27T11:23:35Z-
dc.date.accessioned2016-10-25T18:25:40Z-
dc.date.available2014-05-27T11:23:35Z-
dc.date.available2016-10-25T18:25:40Z-
dc.date.issued2008-07-01-
dc.identifierhttp://dx.doi.org/10.1111/j.1443-1661.2008.00794.x-
dc.identifier.citationDigestive Endoscopy, v. 20, n. 3, p. 146-149, 2008.-
dc.identifier.issn0915-5635-
dc.identifier.issn1443-1661-
dc.identifier.urihttp://hdl.handle.net/11449/70452-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/70452-
dc.description.abstractCaustic ingestion is a leading cause of esophageal stenosis in children. Herein we report four cases using mitomycin C (MMC), a drug that inhibits cell division, protein synthesis and fibroblast proliferation and has been used as an adjuvant therapy for caustic esophageal stenosis that is recalcitrant to conventional dilation techniques. A retrospective chart review was performed on four pediatric patients with severe, recurrent esophageal stricture after caustic ingestion. The patients had required six to 20 esophageal dilations over a 4-16-month period before MMC application. MMC was applied after an endoscopic dilation on saturated pledgets at a dose of 0.1 mg/mL for 2 min in the area where the strictures had been lyzed. From the four children treated with MMC, two have been asymptomatic for 16 and 20 months and two still require esophageal dilation, however, at longer intervals. All patients have shown satisfactory weight gain with food intake exclusively per oral. Although further studies are required, there is strong evidence that MMC is a safe and effective adjuvant therapy in the treatment of esophageal caustic stenosis. © 2008 The Authors.en
dc.format.extent146-149-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectCaustic stenosis-
dc.subjectEsophageal stenosis-
dc.subjectMitomycin C-
dc.subjectmitomycin C-
dc.subjectadjuvant therapy-
dc.subjectcase report-
dc.subjectchild-
dc.subjectesophagitis-
dc.subjectesophagoscopy-
dc.subjectesophagus stenosis-
dc.subjectesophagus surgery-
dc.subjectfemale-
dc.subjecthuman-
dc.subjectmale-
dc.subjectmedical record review-
dc.subjectsurgical technique-
dc.subjecttreatment outcome-
dc.subjecttreatment response-
dc.titleTherapeutic option for children with esophageal caustic stenosisen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.description.affiliationBotucatu School of Medicine Department of Surgery, Rubião Jr s/n, Botucatu, SP 18618-970-
dc.description.affiliationState of Sao Paulo University Botucatu School of Medicine, Botucatu, SP-
dc.identifier.doi10.1111/j.1443-1661.2008.00794.x-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofDigestive Endoscopy-
dc.identifier.scopus2-s2.0-44649178168-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.